Thromboxane A2-induced arrhythmias in the anesthetized rabbit

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 4, 2006, Pages

  Wacker, Michael J ^a   Best, Shaun R ^a   Kosloski, Lisa M ^a   Stachura, Christopher J ^a   Smoot, Rory L ^a   Porter, Charles B ^b   Orr, James A ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Autonomic nervous system; Coronary blood flow; Phenylephrine; Prostaglandin F 2 ; SQ 29548; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; PHENYLEPHRINE; PROPRANOLOL DERIVATIVE; PROSTAGLANDIN F2 ALPHA; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; VASOCONSTRICTOR AGENT;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; EFFERENT NERVE; ELECTRIC ACTIVITY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; IN VIVO STUDY; MALE; NONHUMAN; PARASYMPATHETIC NERVE; PERIPHERAL NERVE; PRIORITY JOURNAL; RABBIT; ST SEGMENT; VAGOTOMY; ANIMAL; BLOOD FLOW VELOCITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART RATE; METABOLISM; PATHOPHYSIOLOGY;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANESTHESIA; ANIMALS; ARRHYTHMIA; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; HEART RATE; MALE; RABBITS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 33646120329     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00930.2005     Document Type: Article

References (54)

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, and Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483: 285-293, 2000.
2. Allen JD, Pantridge JF, and Shanks RG. Effects of lignocaine, propranolol and bretylium on ventricular fibrillation threshold. Am J Cardiol 28: 555-562, 1971.
3. 2 mimetic. Am J Physiol Heart Circ Physiol 266: H2320-H2326, 1994.
4. 2. Science 296: 539-541, 2002.
5. Coker SJ. Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 16: 633-641, 1984.
6. Coker SJ and Parratt JR. AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds. Br J Pharmacol 86: 259-264, 1985.
7. Coker SJ, Parratt JR, Ledingham IM, and Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291: 323-324, 1981.
8. 2 on some isolated smooth muscle preparations. Br J Pharmacol 73: 773-778, 1981.
9. Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306: 384-385, 2004.
10. Deedwania PC. Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes. Am J Cardiol 65: 43A-52A, 1990.
11. Dogan S, Turnbaugh D, Zhang M, Cofie DQ, Fugate RD, and Kem DC. Thromboxane A2 receptor mediation of calcium and calcium transients in rat cardiomyocytes. Life Sci 60: 943-952, 1997.
12. Fitzgerald JD. Beta blocking drugs as anti-arrhythmic agents. Int J Clin Pharmacol Biopharm 11: 235-244, 1975.
13. 2 stimulates ischemically sensitive cardiac afferents (Abstract). FASEB J 16: A830, 2002.
14. Gadsby DC, Wit AL, and Cranefield PF. The effects of acetylcholine on the electrical activity of canine cardiac Purkinje fibers. Circ Res 43: 29-35, 1978.
15. Hale SL and Kloner RA. Protection of myocardium by transient, preischemic administration of phenylephrine in the rabbit. Coron Artery Dis 5: 605-610, 1994.
16. Hamberg M, Svensson J, and Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994-2998, 1975.
17. Hampton JR. Choosing the right beta-blocker. A guide to selection. Drugs 48: 549-568, 1994.
18. Hirsh PD, Hillis LD, Campbell WB, Firth BG, and Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304: 685-691, 1981.
19. 2 analog (U46619) of calcium dynamics in isolated rat cardiomyocytes. J Pharmacol Exp Ther 264: 336-344, 1993.
20. 2 mimetic, U46,619, on pulmonary vagal afferents in the cat. Respir Physiol 87: 383-396, 1992.
21. 2. Brain Res 744: 175-178, 1997.
22. Kerzner J, Wolf M, Kosowsky BD, and Lown B. Ventricular ectopic rhythms following vagal stimulation in dogs with acute myocardial infarction. Circulation 47: 44-50, 1973.
23. 2) receptor antagonist to rabbit and pig heart membrane protein. Prostaglandins Leukot Essent Fatty Acids 47: 153-157, 1992.
24. Li Y, Kang JX, and Leaf A. Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes. Prostaglandins 54: 511-530, 1997.
25. Mantelli L, Amerini S, Rubino A, and Ledda F. Effects of thromboxane agonists on cardiac adrenergic neurotransmission. Eur J Pharmacol 213: 79-85, 1992.
26. Martins JB and Zipes DP. Effects of sympathetic and vagal nerves on recovery properties of the endocardium and epicardium of the canine left ventricle. Circ Res 46: 100-110, 1980.
27. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999.
28. Moncada S and Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30: 293-331, 1978.
29. Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, Kazatchkine M, Eugene L, Thomas D, and Grosgogeat Y. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 84: 2054-2062, 1991.
30. Myers RW, Pearlman AS, Hyman RM, Goldstein RA, Kent KM, Goldstein RE, and Epstein SE. Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. Circulation 49: 943-947, 1974.
31. Nakamura F, Minshall RD, Le Breton GC, and Rabito SF. Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension 28: 444-449, 1996.
32. Perlini S, Solda PL, Piepoli M, Sala-Gallini G, Calciati A, Finardi G, and Bernardi L. Determinants of respiratory sinus arrhythmia in the vagotomized rabbit. Am J Physiol Heart Circ Physiol 269: H909-H915, 1995.
33. Ponicke K, Giessler C, Grapow M, Heinroth-Hoffmann I, Becker K, Osten B, and Brodde OE. FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes. Br J Pharmacol 129: 1723-1731, 2000.
34. Pratt C and Lichstein E. Ventricular antiarrhythmic effects of beta-adrenergic blocking drugs: a review of mechanism and clinical studies. J Clin Pharmacol 22: 335-347, 1982.
35. Prystowsky EN, Jackman WM, Rinkenberger RL, Heger JJ, and Zipes DP. Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in humans. Evidence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ Res 49: 511-518, 1981.
36. Reffelmann T and Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol 283: H1099-H1107, 2002.
37. Sakuma I, Gross SS, and Levi R. Positive inotropic effect of the thromboxane analog U-46619 on guinea pig left atrium: mediation by specific receptors and association with increased phosphoinositide turnover. Can J Physiol Pharmacol 67: 943-949, 1989.
38. Scherlag BJ, Kabell G, Harrison L, and Lazzara R. Mechanisms of bradycardia-induced ventricular arrhythmias in myocardial ischemia and infarction. Circulation 65: 1429-1434, 1982.
39. Stinnett HO, Sepe FJ, and Mangusson MR. Rabbit carotid baroreflexes after carotid sympathectomy, vagotomy, and beta blockade. Am J Physiol Heart Circ Physiol 241: H600-H605, 1981.
40. 2α mediate inflammatory tachycardia. Nat Med 11: 562-566, 2005.
41. Trachte GJ. Thromboxane agonist (U46619) potentiates norepinephrine efflux from adrenergic nerves. J Pharmacol Exp Ther 237: 473-477, 1986.
42. Trachte GJ, Hook PJ, Kemp JR, Acosta EP, and Ziegler RJ. Thromboxane synthesis and actions in isolated adrenergic nerve (pheochromocytoma-12) cells. J Pharmacol Exp Ther 247: 43-46, 1988.
43. Tse WW, Han J, and Yoon MS. Effect of acetylcholine on automaticity of canine Purkinje fibers. Am J Physiol 230: 116-119, 1976.
44. 2 synthetase inhibitor, on ventricular arrhythmias induced by coronary artery occlusion in rats. Jpn Circ J 60: 349-354, 1996.
45. Vane JR. Biomedicine. Back to an aspirin a day? Science 296: 474-475, 2002.
46. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, and Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68: 1471-1481, 1991.
47. Vatner SF. Regulation of coronary resistance vessels and large coronary arteries. Am J Cardiol 56: 16E-22E, 1985.
48. 2 mimetic evokes a bradycardia mediated by stimulation of cardiac vagal afferent nerves. Am J Physiol Heart Circ Physiol 282: H482-H490, 2002.
49. 2 receptor mRNA in rabbit nodose ganglion neurons. Neurosci Lett 386: 121-126, 2005.
50. 2-induced coronary chemoreflex. Am J Physiol Heart Circ Physiol 284: H867-H875, 2003.
51. Wainwright CL and Parratt JR. The effects of L655,240, a selective thromboxane and prostaglandin endoperoxide antagonist, on ischemiaand reperfusion-induced cardiac arrhythmias. J Cardiovasc Pharmacol 12: 264-271, 1988.
52. Weiss T, Lattin GM, and Engelman K. Vagally mediated suppression of premature ventricular contractions in man. Am Heart J 89: 700 -707, 1975.
53. Williams DO and Most AS. Responsiveness of the coronary circulation to brief vs. sustained alpha-adrenergic stimulation. Circulation 63: 11-16, 1981.
54. Woodman OL. Noradrenaline-induced constriction of large and small coronary arteries in the anaesthetized dog. J Auton Pharmacol 9: 53-61, 1989.